Skip to Main Content

WASHINGTON — A new proposal that senators claim would fix insulin pricing would actually allow drugmakers to lock in their current profits from the medicine for the foreseeable future.

The bill, introduced Wednesday by Sens. Jeanne Shaheen (D-N.H.) and Susan Collins (R-Maine), proposes a complicated redesign of how insulin products are priced, and what patients pay for them. The proposal could help a minority of patients who use insulin, and Senate leadership is hoping to speed it to a vote this summer.


But the fix would likely spread costs to all Medicare patients, insurers, and the federal government, without actually changing how much drug makers make on the medicine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.